1887
Preview this article:
Zoom in
Zoomout

On the enhancement of anti-neurotoxin antibody production by subcomponents HA1 and HA3b of type B 16S toxin-haemagglutinin, Page 1 of 1

| /docserver/preview/fulltext/micro/152/7/1891a-1.gif

There is no abstract available for this article.
Use the preview function to the left.

Loading

Article metrics loading...

/content/journal/micro/10.1099/mic.0.28862-0
2006-07-01
2019-10-22
Loading full text...

Full text loading...

/deliver/fulltext/micro/152/7/1891a.html?itemId=/content/journal/micro/10.1099/mic.0.28862-0&mimeType=html&fmt=ahah

References

  1. Aoki, K. R. ( 2002; ). Immunologic and other properties of therapeutic botulinum toxin serotypes. In Scientific and Therapeutic Aspects of Botulinum Toxin, pp. 103–113. Edited by M. F. Brin, M. Hallett & J. Jankovic. Philadelphia: Lippincott Williams & Wilkins.
  2. Arimitsu, H., Inoue, K., Sakaguchi, Y., Lee, J., Fujinaga, Y., Watanabe, T., Ohyama, T., Hirst, R. & Oguma, K. ( 2003; ). Purification of fully activated Clostridium botulinum serotype B toxin for treatment of patients with dystonia. Infect Immun 71, 1599–1603.[CrossRef]
    [Google Scholar]
  3. Atassi, M. Z. ( 1977; ). Chemical modification and cleavage of proteins and chemical strategy in immunochemical studies of proteins. In Immunochemistry of Proteins, vol. 1, pp. 1–161. Edited by M. Z. Atassi. New York: Plenum.
  4. Atassi, M. Z. ( 1984; ). Antigenic structures of proteins. Their determination has revealed important aspects of immune recognition and generated strategies for synthetic mimicking of protein binding sites. Eur J Biochem 145, 1–20.[CrossRef]
    [Google Scholar]
  5. Atassi, M. Z. ( 2002; ). Immune recognition and cross-reactivity of botulinum neurotoxins. In Scientific and Therapeutic Aspects of Botulinum Toxins, pp. 385–408. Edited by M. F. Brin, M. Hallett & J. Jankovic. Philadelphia: Lippincott Williams & Wilkins.
  6. Atassi, M. Z. ( 2004; ). Basic immunological aspects of botulinum toxin therapy. Mov Disord Suppl 8, S68–S84.
    [Google Scholar]
  7. Atassi, M. Z. & Oshima, M. ( 1999; ). Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins. Crit Rev Immunol 19, 219–260.
    [Google Scholar]
  8. Atassi, M. Z., Dolimbek, B. Z., Hayakari, M., Middlebrook, J. L., Whitney, B. & Oshima, M. ( 1996; ). Mapping of the antibody-binding regions on botulinum neurotoxin H-Chain domain 855–1296 with anti-toxin antibodies from three host species. J Protein Chem 15, 691–700.[CrossRef]
    [Google Scholar]
  9. Atassi, M. Z., Dolimbek, G. S., Deitiker, P. R., Aoki, K. R. & Dolimbek, B. Z. ( 2005; ). Submolecular recognition profiles in two mouse strains of non-protective and protective antibodies against botulinum neurotoxin A. Mol Immunol 42, 1509–1520.[CrossRef]
    [Google Scholar]
  10. Borodic, G. E., Acquadro, M. & Johnson, E. A. ( 2001; ). Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opin Investig Drugs 10, 1531–1544.[CrossRef]
    [Google Scholar]
  11. Brashear, A., Lew, M. F., Dykstra, D. D. & 10 other authors ( 1999; ). Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 53, 1439–1446.[CrossRef]
    [Google Scholar]
  12. Brashear, A., McAfee, A. L., Kuhn, E. R. & Fyffe, J. ( 2004; ). Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil 85, 705–709.[CrossRef]
    [Google Scholar]
  13. Callaway, J. E., Arezzo, J. C. & Grethlein, A. J. ( 2002; ). Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology. Dis Mon 48, 367–383.[CrossRef]
    [Google Scholar]
  14. Chen, J., Fitos, I. & Hage, D. S. ( 2006; ). Chromatographic analysis of allosteric effects between ibuprofen and benzodiazepines on human serum albumin. Chirality 18, 24–36.[CrossRef]
    [Google Scholar]
  15. Coyle, E. M., Blazer, L. L., White, A. A., Hess, J. L. & Boyle, M. D. ( 2006; ). Practical applications of high-affinity, albumin-binding proteins from a group G streptococcal isolate. Appl Microbiol Biotechnol 71, 39–45.[CrossRef]
    [Google Scholar]
  16. Dolimbek, G. S., Dolimbek, B. Z., Aoki, K. R. & Atassi, M. Z. ( 2005; ). Mapping of the antibody and T cell recognition profiles of the HN domain (residues 449–859) of the heavy chain of botulinum neurotoxin A in two high-responder mouse strains. Immunol Invest 34, 119–142.
    [Google Scholar]
  17. Dressler, D. & Bigalke, H. ( 2005; ). Botulinum toxin type B de novo therapy of cervical dystonia frequency of antibody induced therapy failure. J Neurol 252, 904–907.[CrossRef]
    [Google Scholar]
  18. Göschel, H., Wohlfarth, K., Frevert, J., Dengler, R. & Bigalke, H. ( 1997; ). Botulinum A toxin therapy: neutralizing and nonneutralizing Abs – therapeutic consequences. Exp Neurol 147, 96–102.[CrossRef]
    [Google Scholar]
  19. Inagi, K., Ford, C. N., Rodriquez, A. A., Schultz, E., Bless, D. M. & Heisey, D. M. ( 1997; ). Efficacy of repeated botulinum toxin injections as a function of timing. Ann Otol Rhinol Laryngol 106, 1012–1019.[CrossRef]
    [Google Scholar]
  20. Jankovic, J. ( 2002; ). Botulinum toxin clinical implications of antigenicity and immunoresistance. In Scientific and Therapeutic Aspects of Botulinum Toxin, pp. 409–415. Edited by M. F. Brin, M. Hallett & J. Jankovic. Philadelphia: Lippincott Williams & Wilkins.
  21. Jankovic, J. ( 2004; ). Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatr 75, 951–957.[CrossRef]
    [Google Scholar]
  22. Jankovic, J., Hunter, C., Atassi, M. Z., Dolimbek, B. Z., Dolimbek, G. S. & BOS Research Group ( 2005; ). Botulinum toxin type B observational study (BOS). Mov Disord 20, S31.
    [Google Scholar]
  23. Jemmerson, R. & Margoliash, E. ( 1978; ). In Immunobiology of Proteins and Peptides, vol. 1, pp. 119–129, Edited by M. Z. Atassi & A. B. Stavitsky. New York: Plenum.
  24. Jemmerson, R. & Margoliash, E. ( 1979; ). Topographic antigenic determinants on cytochrome c. Immunoadsorbent separation of the rabbit antibody populations directed against horse cytochrome. J Biol Chem 254, 12706–12716.
    [Google Scholar]
  25. Komatsu, T., Ohmichi, N., Nakagawa, A., Zunszain, P. A., Curry, S. & Tsuchida, E. ( 2005; ). O2 and CO binding properties of artificial hemoproteins formed by complexing iron protoporphyrin IX with human serum albumin mutants. J Am Chem Soc 127, 15933–15942.[CrossRef]
    [Google Scholar]
  26. Lee, J.-C., Yokota, K., Arimitsu, H. & 7 other authors ( 2005; ). Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology 151, 3739–3747.[CrossRef]
    [Google Scholar]
  27. Lin, H. C., Chen, P. C., Cheng, T. J. & Chen, R. L. ( 2004; ). Formation of tannin-albumin nano-particles at neutral pH as measured by light scattering techniques. Anal Biochem 325, 117–120.[CrossRef]
    [Google Scholar]
  28. Marini, I., Moschini, R., Corso, A. D. & Mura, U. ( 2005; ). Chaperone-like features of bovine serum albumin: a comparison with alpha-crystallin. Cell Mol Life Sci 62, 3092–3099.[CrossRef]
    [Google Scholar]
  29. Means, G. E. & Feeney, R. E. ( 1971; ). Chemical Modification of Proteins. San Francisco: Holden-Day.
  30. Militello, V., Casarino, C., Emanuele, A., Giostra, A., Pullara, F. & Leone, M. ( 2004; ). Aggregation kinetics of bovine serum albumin studied by FTIR spectroscopy and light scattering. Biophys Chem 107, 175–187.[CrossRef]
    [Google Scholar]
  31. Oliva, A., Santovena, A., Farina, J. & Llabres, M. ( 2003; ). Effect of high shear rate on stability of proteins: kinetic study. J Pharm Biomed Anal 33, 145–155.[CrossRef]
    [Google Scholar]
  32. Poewe, W., Deuschl, G., Nebe, A. & 8 other authors ( 1998; ). What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatr 64, 13–17.[CrossRef]
    [Google Scholar]
  33. Reichlin, M., Nisonoff, A. & Margoliash, E. ( 1970; ). Immunological activity of cytochrome c. 3. Enhancement of antibody detection and immune response initiation by cytochrome c polymers. J Biol Chem 245, 947–954.
    [Google Scholar]
  34. Rosenberg, J. S., Middlebrook, J. L. & Atassi, M. Z. ( 1997; ). Localization of the regions on the C-terminal domain of the heavy chain of botulinum toxin A recognized by T-lymphocytes and by antibodies after immunization of mice with pentavalent toxoid. Immunol Invest 26, 491–504.[CrossRef]
    [Google Scholar]
  35. Rozak, D. A., Orban, J. & Bryan, P. N. ( 2005; ). G148-GA3: a streptococcal virulence module with atypical thermodynamics of folding optimally binds human serum albumin at physiological temperatures. Biochim Biophys Acta 1753, 226–233.[CrossRef]
    [Google Scholar]
  36. Vaiana, S. M., Emanuele, A., Palma-Vittorelli, M. B. & Palma, M. U. ( 2004; ). Irreversible formation of intermediate BSA oligomers requires and induces conformational changes. Proteins 55, 1053–1062.[CrossRef]
    [Google Scholar]
  37. Yablon, S. A., Daggett, S. & Brin, M. F. ( 2005; ). Toxin neutralizing antibody formation with botulinum toxin type A (BoNTA) treatment. In 57th Annual Meeting of the American Academy of Neurology, Abstract P01.153, 12 April 2005, Miami Beach, Florida.
  38. Young, C. R. & Atassi, M. Z. ( 1982; ). Genetic control of the immune response to myoglobin. IX. Overcoming genetic control of antibody response to antigenic sites by increasing the dose of antigen used in immunization. J Immunogen 9, 343–351.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/micro/10.1099/mic.0.28862-0
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error